9,448 Shares in Moderna, Inc. $MRNA Purchased by Ieq Capital LLC

Ieq Capital LLC bought a new stake in Moderna, Inc. (NASDAQ:MRNA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 9,448 shares of the company’s stock, valued at approximately $662,000.

Several other institutional investors have also modified their holdings of MRNA. Vanguard Group Inc. raised its position in shares of Moderna by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 41,584,782 shares of the company’s stock valued at $1,226,335,000 after buying an additional 399,487 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Moderna in the 2nd quarter valued at about $2,142,877,000. Capital World Investors purchased a new stake in Moderna during the fourth quarter worth approximately $378,299,000. Invesco Ltd. grew its stake in shares of Moderna by 15.7% in the third quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock valued at $212,223,000 after buying an additional 1,115,131 shares in the last quarter. Finally, Theleme Partners LLP boosted its holdings in Moderna by 8.6% in the 2nd quarter. Theleme Partners LLP now owns 7,868,810 shares of the company’s stock worth $217,100,000 after acquiring an additional 626,420 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Down 3.3%

Shares of NASDAQ:MRNA opened at $137.99 on Friday. The company’s fifty day moving average is $77.11 and its two-hundred day moving average is $59.73. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $176.66. The stock has a market capitalization of $55.09 billion, a price-to-earnings ratio of -17.27 and a beta of 0.91.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. The business had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($2.13) EPS. Equities analysts anticipate that Moderna, Inc. will post -6.11 EPS for the current year.

Key Stories Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck reported that their personalized mRNA melanoma vaccine, intismeran, combined with Keytruda, met the goals of a Phase 3 study involving 1,137 patients. The treatment reduced the risk of melanoma recurrence and distant spread versus Keytruda alone, strengthening the case for Moderna’s oncology pipeline and the commercial potential of the partnership. Reuters cancer vaccine breakthrough article
• Positive Sentiment: The U.S. FDA approved Moderna’s updated 2026–2027 Spikevax and mNEXSPIKE COVID-19 vaccines, targeting the XFG subvariant. The approval preserves access to the seasonal COVID-19 vaccine market, though future demand remains an important uncertainty. Reuters FDA approval article
• Positive Sentiment: Argus upgraded Moderna from “Hold” to “Buy” and assigned a $180 price target, indicating additional potential upside based on the company’s oncology opportunity and recent clinical progress. Argus upgrade article
• Neutral Sentiment: Jim Cramer advised a viewer to hold Moderna after the stock’s sharp rally, reflecting continued optimism about the Phase 3 cancer-vaccine result but also caution following the run-up. Jim Cramer Moderna commentary
• Negative Sentiment: Moderna priced an upsized $2.6 billion offering of zero-coupon convertible senior notes due 2032, increased from the initially proposed $2.0 billion. Proceeds may fund oncology investments and debt repayment, but the larger financing raised concerns about future share dilution and explains much of the selling pressure. Moderna convertible notes offering
• Negative Sentiment: BioNTech’s decision to halt a mid-stage personalized mRNA colorectal-cancer vaccine trial after a review weakened sentiment across the mRNA oncology sector, raising broader questions about the difficulty of translating promising technology into successful cancer treatments. BioNTech colorectal cancer trial article

Analysts Set New Price Targets

A number of brokerages recently commented on MRNA. Piper Sandler reissued an “overweight” rating on shares of Moderna in a report on Monday, August 3rd. Bradesco Corretora upgraded Moderna to an “outperform” rating in a research note on Friday. Loop Capital set a $135.00 price target on shares of Moderna in a research note on Wednesday, August 19th. The Goldman Sachs Group upped their price target on shares of Moderna from $67.00 to $120.00 and gave the company a “neutral” rating in a report on Wednesday, August 19th. Finally, Bank of America raised shares of Moderna from an “underperform” rating to a “neutral” rating in a report on Wednesday, August 19th. Seven investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, Moderna has a consensus rating of “Hold” and an average target price of $80.53.

Insider Buying and Selling

In related news, President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the transaction, the president owned 1,483,848 shares in the company, valued at $76,225,271.76. The trade was a 3.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the sale, the insider owned 67,468 shares in the company, valued at $3,373,400. The trade was a 4.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 10.80% of the company’s stock.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.